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Background: High consumption of fish carries a lower risk of cardiovascular disease as a consequence of dietary
omega-3 long chain polyunsaturated fatty acid (n-3 PUFA; especially EPA and DHA) content. A controversy exists
about the component/s responsible of these beneficial effects and, in consequence, which is the best proportion
between both fatty acids. We sought to determine, in healthy Wistar rats, the proportions of EPA and DHA that
would induce beneficial effects on biomarkers of oxidative stress, and cardiovascular disease risk.
Methods: Female Wistar rats were fed for 13 weeks with 5 different dietary supplements of oils; 3 derived from fish
(EPA/DHA ratios of 1:1, 2:1, 1:2) plus soybean and linseed as controls. The activities of major antioxidant enzymes
(SOD, CAT, GPX, and GR) were determined in erythrocytes and liver, and the ORAC test was used to determine the
antioxidant capacity in plasma. Also measured were: C reactive protein (CRP), endothelial dysfunction (sVCAM and
sICAM), prothrombotic activity (PAI-1), lipid profile (triglycerides, cholesterol, HDLc, LDLc, Apo-A1, and Apo-B100),
glycated haemoglobin and lipid peroxidation (LDL-ox and MDA values).
Results: After three months of nutritional intervention, we observed statistically significant differences in the
ApoB100/ApoA1 ratio, glycated haemoglobin, VCAM-1, SOD and GPx in erythrocytes, ORAC values and LDL-ox.
Supplementation with fish oil derived omega-3 PUFA increased VCAM-1, LDL-ox and plasma antioxidant capacity
(ORAC). Conversely, the ApoB100/ApoA1 ratio and percentage glycated haemoglobin decreased.
Conclusions: Our results showed that a diet of a 1:1 ratio of EPA/DHA improved many of the oxidative stress
parameters (SOD and GPx in erythrocytes), plasma antioxidant capacity (ORAC) and cardiovascular risk factors
(glycated haemoglobin) relative to the other diets.
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Diets with high fish content have been associated with a
low cardiovascular disease (CVD) risk. Of particular note
are the n-3 polyunsaturated fatty acids (n-3 PUFA):
eicosapentaenoic acid (EPA, 20:5 n-3) and docosahexaenoic
acid (DHA, 22:6 n-3).
Fish are the major food sources of DHA and EPA and
are carried in the circulation as triglycerides, especially
phospholipids [1]. There are several experimental studies
that show that the n-3 PUFA perform several functions
in relation to the structure and function of the membrane,
tissue metabolism, and gene regulation [2]. These fatty acids
play important roles in reducing hypertriglyceridaemia
[3,4], low density lipoprotein cholesterol (LDLc), very low
density lipoprotein cholesterol (VLDLc), and increasing
high density lipoprotein cholesterol (HDLc) concentrations
[5] as well as various components of these molecules e.g.
ApoA1 and ApoB100 of HDL and LDL/VLDL respectively.
EPA and DHA improve hypertension [6], insulin sensitivity
and glycaemia [7]. Oxidative stress and vascular endothelial
dysfunction also play a critical role in the pathogenesis of
CVD. Increased oxidative stress underlies the pathophysi-
ology of hypertension and atherosclerosis by directly
affecting the cells of the vascular wall [8]. Higher
levels of soluble intercellular adhesion molecule-1
(sICAM-1) and soluble vascular cell adhesion molecule-1
(sVCAM-1) have been associated with an increased risk of
ischaemic disease and peripheral artery disease mediated, in
part, by C reactive protein (CRP) [9]. Type 1 plasminogen
activator inhibitor (PAI-1) is also related to metabolic
syndrome, obesity, and CVD [5].
The amount of n-3 PUFA necessary to provide health
benefits is unknown [10] as are the proportions of EPA
and DHA that provide the greatest benefit. The majority
of the clinical studies carried-out to date use fish-oil
derived dietary supplements, but with a higher EPA/DHA
ratio than that commonly found in the fish themselves
[11,12], and it would not trigger the effects in vivo
compared to the ratio contained in fish. EPA and DHA
derived from fish oils have demonstrable cardiovascular
disease benefits in observational studies and experimental
trials which, mainly, have investigated their effects in
combination. As such, little is known of the potentially
different effects of EPA and DHA, especially regarding
which has the better protective effect on CVD [2].
Hence, our present study seeks to determine the
proportion of EPA/DHA that is best able to achieve a
protective effect of the n-3 PUFA on CVD risk factors.
Three dietary interventions with the optimal relation n-3/
n-6 and different EPA/DHA ratios (1:1, 2:1, 1:2) were eval-
uated in a healthy animal model. Soybean and linseed oils
were used as control diets. Soybean is a rich source of
linoleic acid (LA, 18:2 n-6), while linseed oil has an
elevated content of alpha-linolenic acid (ALA, 18:3 n-3) [13].Parameters of oxidative stress, inflammation, endothelial
dysfunction, prothrombotic state, protein glycation,
lipid peroxidation, and lipid profile were determined
as risk factors or biomarkers indicative of CVD risk.
Results
Anthropomorphic measures
None of the nutritional interventions, irrespective of the
proportions of EPA/DHA (1:1, 2:1, 1:2) or soybean or
linseed oil supplements, significantly increased the
weight of the animals (260.3 ± 11; 259.3 ± 12; 255.5 ± 10;
259.1 ± 8; 266.3 ± 9, respectively). Abdominal fat tissue, as
a percentage of overall body weight, was not significantly
different in test diets compared to that of the animals on
the control diets (3.89 ± 1.2; 3.62 ± 0.8; 4.12 ± 0.7; 4.3 ± 0.7;
4.2 ± 0.9, respectively).
Antioxidant status and oxidative stress
The biomarkers of antioxidant status and oxidative
stress are summarised in Table 1.
The concentrations of antioxidant enzymes in erythro-
cytes indicated an activation of these enzymes in fish-oil
diets.
SOD values were higher in 1:1 EPA/DHA diet followed
by 2:1 EPA/DHA, compared to the other 3 diets. GPx
values were also higher in 1:1 and 2:1 EPA/DHA. There
was a trend, albeit not statistically significant, towards
higher CAT and lower GR values in fish-oil diets
compared to the control diets.
These results indicated that fish-oil diets, especially 1:1
and 2:1 EPA/DHA, had improved values of antioxidant
enzymes than did soybean and linseed oils.
The two control diets (soybean and linseed) had no
significant differences between them with respect to the
values of erythrocyte antioxidant enzymes.
Finally, the plasma antioxidant capacity (ORAC) was
significantly higher in the 1:1 diet than in the other diets.
This result is in agreement with the high SOD and GPx
values found in this supplemented group.
Lipid peroxidation
The mean LDL-ox values indicated higher oxidation in
fish-oil diets than controls. LDL-ox of diets with 2:1 and
1:2 EPA/DHA ratios were significantly higher, compared
to soybean and linseed diets. The EPA/DHA (1:1) group
did not show significant differences with respect to
control groups (Table 1).
Mean values of MDA in the liver were not significantly
different between groups.
Lipid profile
TG, CHOL, LDLc, HDLc, LDLc/HDLc, Apo A1 and Apo
B100 were not statistically significantly different between
supplemented groups (Table 2).
Table 1 Antioxidant and oxidative stress biomarkers in blood and liver of Wistar rats fed the oil supplements
Biomarkers EPA/DHA 1:1 EPA/DHA 2:1 EPA/DHA 1:2 Soybean oil Linseed oil
Mean ± SD Mean ± SD p Mean ± SD P Mean ± SD p Mean ± SD p
Erythrocytes
SOD (U/g Hb) 2129.2 ± 586.5 1880.9 ± 341.2 1226.1 ± 517.4 a0.023 1443.8 ± 426.2 1230.6 ± 283.9 a0.017
CAT (mmol/min/g Hb) 57.4 ± 11.1 76.7 ± 28.2 61.4 ± 13.2 41.5 ± 34.6 37.2 ± 20.9
GR (U/g Hb) 0.40 ± 0.08 0.734 ± 0.21 0.63 ± 0.35 0.93 ± 0.18 0.75 ± 0.20
GPx (U/g Hb) 107.1 ± 15.0 116.7 ± 30.7 a0.007 67.7 ± 34.5 a0.026 101.5 ± 38.2 71.1 ± 9.6 a0.002
b0.007 b0.001
Plasma
ORAC (μmol TE/ml plasma) 48.15 ± 16.96 23.56 ± 5.97 a0.023 26.39 ± 9.01 a0.016 30.32 ± 9.64 a0.049 24.71 ± 9.70 a0.033
LDL-ox (ng/mL) 161.53 ± 30.9 212.25 ± 57.4 239.43 ± 70.02 109.03 ± 27.34 b0.007 94.52 ± 14.08 b0.001
c0.001 c0.001
Liver
MDA (μg MDA/ g tissue) 10.29 ± 2.82 7.57 ± 2.55 8.81 ± 3.28 8.12 ± 2.53 6.53 ± 1.24
The data are expressed as mean ± SD (standard deviation). a: difference with respect to EPA/DHA 1:1 supplementation; b: differences with respect to EPA/DHA 2:1
supplementation; c: differences with respect to EPA/DHA 1:2 supplementation.
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ranges observed in other studies [14,15], whereas CHOL
concentrations were increased in all the groups compared
to that observed by Levy et al. [14].
The linseed-oil diet group had significantly higher
values of the ApoB100/ApoA1 ratio, compared to the
1:1, 2:1 and the soybean-oil diets.
Glycaemia control and insulin resistance
The post-intervention glucose concentrations were within
the laboratory reference range in all the groups at <14 mM
[16,17], but the glucose decreases obtained at the end of
the experiment were greater in 1:1 and 2:1 EPA/DHA with
respect to the other diets (Table 2).
All EPA/DHA diets showed significantly lower values
of glycated haemoglobin, relative to the linseed and
soybean oil diets. Glycated haemoglobin concentrations
were not significantly different among the 3 EPA/DHA
diets (Table 2).
The initial concentrations of insulin were within refer-
ence range values (3.5 – 4.4 ng/mL) described by other
authors [17,18] in all groups (results not shown). The
insulin increases observed at the end of the experiment
were not significantly different relative to the baseline
values, and without differences between groups (Table 2).
Following nutritional intervention, the Wistar rats had
HOMA values within laboratory reference ranges (<14)
described by other authors [19]. The linseed group had
significantly lower values compared to the EPA/DHA
1:1 and soybean supplemented groups (Table 2).
Cardiovascular disease risk biomarkers
Linseed diet decreased the sVCAM significantly with
respect to the fish-oil diets while the 2:1 diet hadsignificantly lower values than 1:2 diet (Table 3). The
soybean group had lower values of PAI-1 than the 1:2
EPA/DHA group. No statistically significant differences
were observed between the two control diets with respect
to these biomarkers (Table 3).
No significant differences were observed in CRP and
in sICAM concentrations.
Discussion
Apart from the n-3 PUFA, fish oils contain aminoacids,
vitamins, selenium and other minerals which con-
tribute to the cardiovascular benefit. The majority of
studies with purified EPA or DHA have demon-
strated the bioactivity and effectiveness of these fatty
acids; the implication being that the substantial CVD
benefit of fish oil consumption is related to the n-3
PUFA content [2]. In our study, the supplemented
dose of fish oils (extrapolated to animals) provides
approximately double the amount of EPA and DHA
of the European Union’s recommendation for the main-
tenance of normal blood concentration of triglycerides in
adults [20].
Soybean and linseed oils were used as control diets.
Soybean is a rich source of linoleic acid (LA, 18:2 n-6),
while linseed oil has an elevated content of alpha-linolenic
acid (ALA, 18:3 n-3) [13].
However, all diets had a similar fat and energy content
and, hence, the observed differences can be attributed to
the different ratios of EPA and DHA.
Moreover, the reasoning for using a weekly administra-
tion of the oils was because in a previous test; the daily
feed became very stressing for animals. According to that,
it was decided a weekly doses as has been already
described in the article of Méndez et al. [13].
Table 2 Cardiovascular disease (CVD) risk factors in circulation in Wistar rats fed the different oil supplements
EPA/DHA 1:1 EPA/DHA 2:1 EPA/DHA 1:2 Soybean oil Linseed oil
Biomarkers Mean ± SD Mean ± SD Mean ± SD p Mean ± SD P Mean ± SD p
CV RISK FACTORS
Lipid profile
TG (mg/dL) 86.3 ± 65.1 124.5 ± 102.2 83.1 ± 10.4 108.5 ± 51.9 73.5 ± 25.2
CHOL (mg/dL) 93.3 ± 26.5 98.0 ± 14.8 112.3 ± 20.8 125.8 ± 16.5 118.5 ± 13.5
LDLc (mg/dL) 7.64 ± 3.3 7.4 ± 0.8 8.30 ± 1.3 10.39 ± 2.2 7.4 ± 1.6
HDLc (mg/dL) 37.4 ± 11.1 50.4 ± 25.9 47.3 ± 8.1 51.3 ± 7.8 46.8 ± 5.5
LDLc/HDLc 0.19 ± 0.5 0.20 ± 0.01 0.17 ± 0.01 0.20 ± 0.2 0.19 ± 0.1
ApoA1 (mg/mL) 43.0 ± 11.4 51.7 ± 11.9 47.9 ± 13.8 51.4 ± 13.3 30.6 ± 2.1
ApoB100 (mg/mL) 116.5 ± 16.8 137.0 ± 6.4 139.4 ± 23.8 126.8 ± 13.9 152.7 ± 35.7
ApoB100/ApoA1 2.79 ± 0.51 2.75 ± 0.54 3.10 ± 1.01 2.67 ± 1.11 5.02 ± 1.29 a0.029
b0.019
d0.029
Glycaemia
Glucose increase (mmol/L) −0.75 ± 0.42 −0.15 ± 0.34 0.27 ± 0.49 a0.001 0.53 ± 0.25 a < 0.001 - 0.20 ± 0.31 d0.032
Glycated Haemoglobin (%) 4.14 ± 0.24 4.43 ± 0.72 4.17 ± 0.30 6.39 ± 0.99 a0.003 6.34 ± 1.84 a0.025
b0.007 b0.05
c0.004 c0.032
Insulin increase (ng/mL) 1.40 ± 0.8 0.15 ± 1.90 0.42 ± 0.4 0.9 ± 1.5 0.41 ± 0.5
Homa index 7.0 ± 3.0 4.1 ± 1.8 3.8 ± 1.5 6.9 ± 3.8 2.9 ± 1.1 a0.004
d0.032
The data are expressed as mean ± SD (standard deviation). a: differences with respect to EPA/DHA 1:1 supplementation; b: differences with respect to EPA/DHA 2:1
supplementation; c: differences with respect to EPA/DHA 1:2 supplementation; d: differences with respect to soybean oil supplementation.
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and composition of plasmatic FFA was also evaluated
previously in a recently reported [13] in which we
demonstrated that fish oil supplementation did not
change the total amount of plasmatic FFA, but it altered
the profile of the individual FFA. Animals fed fish oils
exhibited significantly higher levels of EPA (20:5 n-3) andTable 3 Cardiovascular disease (CVD) risk biomarkers in circu
EPA/DHA 1:1 EPA/DHA 2:1 EPA/DH
Biomarkers Mean ± SD Mean ± SD Mean ± SD
CVD RISK MARKERS
Inflammation
CRP (μg/mL) 147.0 ± 20.5 147.1 ± 22.4 140.1 ± 52.7
Thrombotic activity
PAI-1 (μg/mL) 7.48 ± 1.3 8.75 ± 1.8 9.18 ± 1.3
Endothelial dysfunction
sVCAM (μg/mL) 3.41 ± 0.7 3.01 ± 0.4 4.40 ± 1.3
sICAM (ng/mL) 0.59 ± 0.2 0.61 ± 0.2 0.53 ± 0.2
The data are expressed as mean ± SD (standard deviation). a: differences with respe
2:1 supplementation; c: differences with respect to EPA/DHA 1:2 supplementation.DHA (22:6 n-3) compared to those fed soybean oil. The
supplementation with linseed oil provided similar levels of
EPA compared to those observed in the FFA fraction from
animals supplemented with fish oil; however, the amount
of DHA in the FFA fraction was intermediate between
those supplemented with fish and those with soybean oils.
Animals fed linseed oil showed the highest amount of freelation in Wistar rats fed the different oil supplements
A 1:2 Soybean oil Linseed oil
p Mean ± SD P Mean ± SD p
172.9 ± 38.2 142.9 ± 52.0
6.45 ± 0.8 c0.030 7.76 ± 1.1
b0.046 3.36 ± 1.7 2.10 ± 0.4 a0.001
b0.001
c0.003
0.52 ± 0.1 0.59 ± 0.3
ct to EPA/DHA 1:1 supplementation; b: differences with respect to EPA/DHA
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LA in the linseed oil [13].Oxidative stress
Fatty acids with a greater degree of unsaturation in their
molecular structure are more easily oxidised. As a
consequence, diets rich in fish-oils are predisposed to
causing increased oxidative damage in humans and
animals. However, other studies have shown that diets
supplemented with fish oils do not increase cellular
oxidative damage, but may even exert an antioxidant
effect [21,22].
Our results indicate that improvement in activity of SOD
and GPX may explain the higher plasma antioxidant
capacity (ORAC) in the EPA/DHA 1:1 supplemented
group. In other study, n-3 PUFA diet corrected the
decreased ORAC values in diabetic rats, and was probably
due to the increased erythrocyte antioxidant enzymes SOD
and GPX [11]. Our results corroborate this hypothesis.
Further, these results concur with those recently reported
[13] in which we demonstrated that fish-oils, especially
EPA:DHA 1:1, averted protein carbonylation in plasma and
liver. All these findings favour diets rich in EPA and DHA
with respect to antioxidant enzymes; the proportion of 1:1
having a higher relevance than others.Lipid peroxidation
To date, fish-oil supplements have not been unequivocally
shown to prevent oxidation of LDL particles [23]. In our
study, plasma oxidised LDL was higher in the groups
supplemented with fish-oil n-3 PUFA. However,
EPA/DHA 1:1 showed lower values than the other two
diets with n-3 PUFA, and significant differences existed
only among the groups supplemented with 2:1 and 1:2
diets, relative to soybean and linseed.
LDL-ox was lower in the linseed oil group i.e. the ALA
is more effective, in this case, than the administration of
EPA and DHA. This is contrary to that which occurs in
antioxidant protection and protein oxidation, and may be
due to a synergistic effect of ALA i.e. on the one hand
having less unsaturated bonds than EPA and DHA and
hence less susceptible to oxidative attack while, on the
other hand, although the rate of conversion from ALA to
EPA and DHA is low in the organism, small quantities of
these PUFA can contribute to an increase in the levels of
antioxidants that protect LDL.
There were no differences observed in liver MDA
among the different groups, despite differences in the
consumption of n-3 PUFA. As such, although the diets
rich in fish oils do not exercise a clear protection to
plasma LDL oxidation, liver lipoperoxidation were not
affected in these groups, relative to the soybean and
linseed oil groups.Few studies have evaluated MDA levels in liver following
fish-oil administration, and the results have been
contradictory. While some studies concluded that the
administration of fish-oil for 2 months decrease MDA
in rats with partial hepatectomy [24], other studies
demonstrated, following 2 months of nutritional interven-
tion in rats with experimental non-alcoholic fatty liver
disease, that fish-oil derived n-3 PUFA increased liver
MDA concentrations and promoted severe fatty liver [25].
These differences can be due to the different fatty acid
proportions contained in the oils compared to other
molecules with antioxidant capacity such vitamins C and
E that, as well, affect the redox status of the organism.Lipid profile
None of the supplementations increased body-weight
and the amount of abdominal fatty tissue of the animals.
We need to bear in mind that the intake of total fat was
the same in all groups of animals. There were trends,
albeit not statistically significant, towards a decrease in
triglycerides, total cholesterol, LDLc and ApoB100 in the
group supplemented with EPA/DHA 1:1 diet, relative to
the other groups. Decreases in these factors would support
a CVD protective role for EPA/DHA 1:1 diet.
The Apo B100/Apo A1 ratio was significantly reduced
by 1:1, 2:1 and soybean diets, compared to supplementation
with linseed oil. Soybean and fish-oil PUFA reduce the risk
of cardiovascular disease, essentially by improving the lipid
profile, as has been shown by other studies [3,5].Glycaemia control and insulin resistance
Fish-oils are reported to be especially efficient in improving
glycated haemoglobin concentrations in the circulation.
Our study further highlighted that the 1:1 ratio of
EPA/DHA induced the most beneficial improvement
in this factor.
There is a dearth of physiological data regarding the
effect of n-3 PUFA on glucose homeostasis and insulin
resistance in healthy rats. Glycated haemoglobin decreased
on average by 33% in the groups receiving fish-oil supple-
ments compared to those receiving soybean and linseed
diets at the end of the nutritional intervention. This result
concurs with those observed by our group on the
protective effect of supplementation with EPA/DHA
on the carbonylation of proteins [13]. Diets enriched
with fish oil decreased protein carbonylation, especially
the diet with 1:1 ratio of EPA/DHA. The significant
decreases in HbA1c and non-increase in circulating
glucose values observed in the study, indicate a beneficial
effect of marine-fish-derived long chain n-3 PUFA in
healthy animals. These changes would contribute towards
the prevention of some diseases such as metabolic
syndrome and obesity [5,7].
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HOMA index within the reference range [18,19,26]; the
linseed diet group showing the lowest values in these
parameters. As such, the n-3 PUFA did not provoke
increases in plasma insulin in healthy rats.
Conclusions
Our results demonstrate a positive protective effect of
fish-oil supplementation in vivo. Specifically, these
beneficial protective effects depend on the different
proportions of EPA and DHA; the 1:1 proportion of
EPA:DHA being the most beneficial since it improved
antioxidant status, oxidised LDL, Apo-B100/Apo-A1
ratio, and glycated haemoglobin.
Methods
Animals
This study was conducted in compliance with the norms
of the Ethics Committee for Animal Research at the
Centro Superior de Investigaciones Científicas, Spain.
Female Wistar rats (n = 35; 13 weeks of age) were
purchased from Janvier (Le Genest St-Isle, France)
and acclimatised for 8 days prior to the initiation of
the study. The animal room was maintained at a
temperature of 22 ± 2ºC and 50-60% relative humidity
with a 12 h light/dark photoperiod. The animals were
fed a standard pellet diet (Panlab A04, Barcelona,
Spain) and had free access to bottled water and food,
except for a fasting period before sacrifice.
Animals were randomly assigned to five groups (7 rats
each).
Supplementation
Three groups had dietary supplements of fish oils
containing different proportions of EPA/DHA (1:1, 2:1
and 1:2). The 4th group was fed soybean oil and the 5th
with linseed oil. Oils differing in EPA:DHA ratio were
obtained by mixing appropriate quantities of the commer-
cial fish oils. Soybean oil, obtained from unrefined organic
soy oil (first cold pressing), and linseed oil, obtained from
unrefined organic flax oil (first cold pressing). All diets had
a similar fat and energy content [13].
Feeding the selected oil involved weekly oral doses of
0.8 mL/Kg bodyweight for 13 weeks, and administered
by gavage.
Because of the high predisposition of fish oils to
peroxidation, we established quality control to ensure
that the oils did not oxidise during the nutritional
intervention [13].
At the end of the study, the animals were anaesthetised
with ketamine/xylacine (80/10 mg/kg, respectively) by
intra-peritoneal injection. The animals were sacrificed by
cardiac puncture, and exsanguinated. Plasma, serum
and erythrocytes were stored at -80ºC until requiredfor batched analyses. Livers were removed, washed in
phosphate buffered saline, weighed, and immediately
frozen in liquid nitrogen and stored at -80ºC until
required for processing.
Oxidative stress
Antioxidant enzymes in erythrocytes
Superoxide dismutase (SOD) [27], catalase (CAT) [28],
glutathione peroxidase (GPx) [29] and glutathione reduc-
tase (GR) [30] activities were determined in erythrocytes
using standard spectrophotometric methods. The units of
measurement for SOD, GPx and GR are expressed as U/g
Hb, and as mmol/min/g Hb for CAT.
Plasma antioxidant capacity
Plasma antioxidant capacity was measured as the oxygen
radical absorbance capacity (ORAC method) [31]. The
assay measures the oxidative degradation of fluorescein
after being mixed with free radical generators such as
azo-initiator compounds. The units of measurement are
μmol trolox-equivalent/mL plasma (μmol TE/mL).
Lipid peroxidation
Liver malondialdehyde (MDA) levels
Liver samples were homogenised in a sodium phosphate
buffer (200 mM, pH 6.25) and then ultra-centrifuged
(129000 g, 1 h, 4ºC).
Lipid peroxidation was calculated by measuring
MDA concentrations using high performance liquid
chromatography with fluorescence detection (HPLC-FL).
The results are expressed as micrograms of malondialdehyde
per gram of liver [32].
Oxidised LDL
Plasma oxidised LDL (LDL-ox) was measured using
ELISA kits (CUSABIO BIOTECH, China) according to the
manufacturer’s instructions. The units of measurement are
expressed as ng/mL.
Cardiovascular disease risk factors
Lipid profile
The lipid profiles consisting of total plasma triglycerides
(TG), cholesterol (CHOL), HDL cholesterol (HDLc)
and LDL cholesterol (LDLc) were measured by spec-
trophotometric methods (SPINREACT kits, Spain).
ApoA1 and ApoB100 were measured using ELISA kits
(CUSABIO BIOTECH, China). The units of measurement
are expressed as mg/dL for TG, CHOL, HDLc, LDLc and
as mg/mL for APO A1 and APO B100.
Glycaemia control and insulin resistance
Glucose
Animals were fasted for 24 hours and a blood sample
taken from the saphenous vein. The capillary blood was
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glucometer (Bayer Consumer Care AG, Basel, Switzerland).
The results are expressed in mmol/L.
Glycated haemoglobin
Glycated haemoglobin was measured using a spectro-
photometric kit method (SPINREACT, Spain). The units
of measurement are expressed as percentage of total
haemoglobin.
Insulin
Insulin was measured using an ELISA kit (Millipore
Corporation, Billerica, MA, USA). The results are expressed
in ng/mL.
HOMA index
HOMA index (Homeostasis Assessment Model) is an
estimate of insulin resistance and is calculated as:
Fasting insulin (μU/mL) * fasting glucose (mmol/L) / 22.5.
Biomarkers of cardiovascular disease risk
Plasma CRP, sICAM, sVCAM and PAI-1 were measured
by ELISA kits (CUSABIO BIOTECH, China). The results
are expressed as μg/mL for CRP, sVCAM and PAI-1 and
in ng/mL for sICAM.
Statistical analysis
Results were expressed as means and standard devia-
tions for each group of dietary supplementation. The
data were analysed for differences between groups
using one-way analysis of variance (ANOVA). The
SPSS IBM 19 for Windows was used throughout.
When significant differences were found, the means
were compared using the Scheffé post-hoc test. Statistical
significant was set at p < 0.05.
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